Overview

First in Human Study to Evaluate AZD8205 in Patients With Advanced or Metastatic Solid Malignancies

Status:
Recruiting
Trial end date:
2025-05-28
Target enrollment:
Participant gender:
Summary
This research study is studying a new compound, AZD8205, as a possible treatment for advanced or metastatic solid tumours
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
AstraZeneca